Press Release: Neose Technologies Presents Positive NE-180 Phase I Clinical Trial Data

Neose Technologies Presents Positive NE-180 Phase I Clinical Trial Data at American Society of Hematology Annual Meeting HORSHAM, Pa -- Neose Technologies, Inc. presented positive data from its NE-180 Phase I clinical trial during the American Society of Hematology 48th Annual Meeting and Exposition. The data were presented in a poster entitled, “NE-180, a Novel GlycoPEGylated™ Erythropoietin, Demonstrates Dose-Dependent Activity in a Phase 1, Single Dose, Dose Escalation Study in Normal Human Volunteers” on December 9, 2006. NE-180 is being developed for the treatment of anemia associated with chronic kidney disease, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. Conclusions from the study are as follows: > Single doses of NE-180, up to 1.5mcg/kg, were generally well-tolerated with no serious adverse events. > Single doses of NE-180 demonstrated potent, dose-dependent erythropoietic activity. > The results from the Phase I study support a Phase II program in patients with anemia associated with chronic kidney disease, dosed every four weeks, and in cancer patients receiving chemotherapy, dosed every three weeks. The full poster presentation can be found on the Neose website via the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations “We are excited by the data generated in this Phase I trial, particularly the increases in reticulocytes and hemoglobin. These increases support further clinical development of our GlycoPEGylated erythropoietin candidate. We look forward to commencing our Phase II clinical trials in the near future,” said George J. Vergis, Ph.D., Neose president and chief executive officer. About Neose Technologies, Inc. Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $14 billion. For more information, please visit www.neose.com. Neose “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including without limitation the risk that NE-180 could fail in clinical trials or never receive regulatory approval. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose’s Annual Report on Form 10-K for the year ended December 31, 2005, entitled “Factors Affecting the Company’s Prospects” and discussions of potential risks and uncertainties in Neose’s subsequent filings with the SEC.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.